Satokari R, Mattila E, Kainulainen V, Arkkila P E T
Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
Aliment Pharmacol Ther. 2015 Jan;41(1):46-53. doi: 10.1111/apt.13009. Epub 2014 Oct 29.
Faecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection (rCDI). The finding of suitable donor, donor screening and preparation of faecal transplants are challenging in clinical work.
To develop a practical protocol for preparing frozen transplants and to compare the efficacy of previously frozen and fresh faeces in treating rCDI.
Two healthy volunteers acted as universal donors for the frozen faecal preparations, which were prepared by suspending faeces into physiological saline, adding glycerol to a final concentration of 10% and storing at -80 °C. We compared the outcomes of patients with rCDI who had undergone FMT at colonoscopy and received infusion of previously prepared, freeze-stored faeces (n = 23) or fresh faeces from individual (n = 15) or universal donors (n = 11) (total n = 49). Clinical failure was defined as persistent or recurrent symptoms with a positive C. difficile toxin stool test, and a need for new therapy.
At 12 weeks post-FMT, symptoms were resolved in 22 of 23 patients receiving previously frozen faeces, and in all 11 or 14 of 15 patients receiving fresh faeces from the universal or individual donors respectively (totally 25 of 26; P = ns, success rate 96%). Mild transient fever appeared for two patients receiving frozen faeces, but no other significant side effects were observed. 42 patients were followed up for a year post-FMT and the success rate was 88% in both fresh and frozen faeces groups.
Preparation of frozen transplants simplifies the practical aspects of faecal microbiota transplantation without loss of efficacy or safety.
粪便微生物群移植(FMT)是复发性艰难梭菌感染(rCDI)的有效治疗方法。在临床工作中,寻找合适的供体、供体筛查以及粪便移植的准备工作具有挑战性。
制定一种制备冷冻移植粪便的实用方案,并比较先前冷冻粪便和新鲜粪便治疗rCDI的疗效。
两名健康志愿者作为冷冻粪便制剂的通用供体,通过将粪便悬浮于生理盐水中,加入甘油使其终浓度达到10%,并储存在-80°C下制备冷冻粪便制剂。我们比较了在结肠镜检查时接受FMT并输注先前制备的、冷冻保存的粪便(n = 23)或来自个体(n = 15)或通用供体(n = 11)的新鲜粪便(共n = 49)的rCDI患者的治疗结果。临床失败定义为艰难梭菌毒素粪便检测呈阳性且有持续或复发症状,以及需要新的治疗。
FMT后12周,接受先前冷冻粪便的23例患者中有22例症状得到缓解,接受来自通用或个体供体新鲜粪便的15例患者中的11例或14例(共26例中的25例;P = 无显著性差异,成功率96%)症状得到缓解。两名接受冷冻粪便的患者出现轻度短暂发热,但未观察到其他明显副作用。42例患者在FMT后随访一年,新鲜粪便组和冷冻粪便组的成功率均为88%。
冷冻移植粪便的制备简化了粪便微生物群移植的实际操作,且不影响疗效和安全性。